Human Stem Cells Institute PJSC (ISKJ)
Market Closed
6 Jun, 15:45
MOEX MOEX Primary ₽
48. 20
+0.34
+0.7104%
₽
10.49B Market Cap
- P/E Ratio
4.8% Div Yield
6,210 Volume
- Eps
₽ 47.86
Previous Close Want to track ISKJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ISKJ closed Saturday higher at ₽48.2, an increase of 0.7104% from Friday's close, completing a monthly decrease of -15.5571% or -₽8.88. Over the past 12 months, ISKJ stock lost -29.6145%.
The next announced payment will be in In 3 weeks on Jul 06, 2026 for a total of ₽1.044.
The stock of the company had never split.
The company's stock is traded on one exchange.
Human Stem Cells Institute PJSC (ISKJ) FAQ
What is the stock price today?
The current price is ₽48.20.
On which exchange is it traded?
Human Stem Cells Institute PJSC is listed on MOEX.
What is its stock symbol?
The ticker symbol is ISKJ.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 4.8%.
What is its market cap?
As of today, the market cap is 10.49B.
Has Human Stem Cells Institute PJSC ever had a stock split?
No, there has never been a stock split.
Human Stem Cells Institute PJSC Profile
| Biotechnology Industry | Healthcare Sector | Mr. Prikhodko Alexander Viktorovich CEO | MOEX Exchange | X40330106 CUSIP |
| RU Country | - Employees | 22 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Artgen Biotech PJSC is a pioneering biotech company based in Russia, primarily focusing on the healthcare sector. Initially known as the Public Joint-Stock Company "Human Stem Cells Institute," Artgen Biotech has evolved to specialize in the development of an array of medical and healthcare products aimed at addressing various health challenges. Since its inception in 2003, the company has been at the forefront of biotechnological innovation, developing solutions ranging from vaccines to regenerative medicine and gene-activated materials. Artgen Biotech's strategic location in Moscow allows it to tap into a rich pool of scientific talent, enabling groundbreaking research and development activities.
Products and Services
- Betuvax-CoV-2: A vaccine designed specifically to combat the SARS-COV-2 virus, offering a preventive solution against COVID-19.
- Tetraflubet: An influenza vaccine formulated to provide flu protection, enhancing individual and public health resilience against seasonal flu outbreaks.
- Combi 5V: A combination Flu + COVID-19 booster vaccine, crafted to offer dual protection against influenza and COVID-19 with a single administration.
- Betusphere: An immunomodulator aimed at enhancing the body's immune response, providing a bolstered defense mechanism against various pathogens.
- RBT-402: A Human Papillomavirus (HPV) vaccine developed to prevent HPV infections and their consequent health issues, including cervical cancer.
- RBT-501: A specialized vaccine for natural allergies, offering hope for individuals suffering from various allergic reactions.
- Histograft: A Gene-activated material used primarily as an osteoplastic material, represents Artgen Biotech's venture into regenerative medicine, providing solutions for bone regeneration and repair.
- Biobanking, Genetic Research, and Regenerative Medicine Services: These services underscore the company's comprehensive approach to biotechnology, encompassing the preservation of biological samples, exploration of genetic frontiers, and the advancement of regenerative medical treatments.
- Medical Products for Bone Grafting and Regeneration: The lineup includes Xeno-Bone for open operation bone grafting, Inject-Bone for minimally invasive procedures, Inject-Soft for skin and mucous membrane damage, 3D-Bone for volumetric bone defect replacement, Cover Bone for guided bone regeneration, and Supl-Bone for general bone grafting needs.
Contact Information
Address: 18/1 Olimpiysky prospect, Moscow, Russia, 129110
Phone: 7 495 646 8076
Website: https://hsci.ru
